- Statin use before and after breast cancer diagnosis was associated with a 23% and 17% lower risk for breast cancer-related mortality, respectively, in a nationwide Swedish cohort.
Why this matters
- This large observational cohort has more power than most prior studies to detect an inverse association between statin use and breast cancer mortality.
- This study contributes to a large body of observational evidence, but before suggesting that statins be prescribed for patients with breast cancer, a randomized controlled trial is needed.
- Nationwide retrospective observational cohort (n=20,559 diagnosed with breast cancer) from the Swedish Cancer Registry (2005-2008).
- Statin use was obtained from the Swedish Prescription Registry.
- Mortality was obtained from the national cause-of-death registry.
- Funding: European Council; Swedish Research Council; Swedish Cancer Foundation.
- Median follow-up was 61.6 months; 2669 breast cancer-related deaths.
- Simvastatin was the most frequently (82%-93%) prescribed statin.
- Prediagnostic statin use:
- Regular use of statins (vs non- or irregular use) was associated with 23% lower risk for breast cancer-related mortality (HR, 0.77; P=.014).
- High statin use (vs nonuse) was associated with 16% lower risk for breast cancer-related mortality (HR, 0.84; P=.022).
- Postdiagnostic statin use:
- Statin use (vs nonuse) was associated with 17% lower risk for mortality (HR, 0.83; P=.001).
- Observational design.